IP Library Granted Patent US 8,614,274
Granted Patent B2
US 8,614,274 · App. 13/004,604 · Granted Dec 24, 2013

Long-wearing removable pressure sensitive adhesive

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,614,274
App. No.
13/004,604
Granted
Dec 24, 2013
Kind
B2
Abstract

A medical grade adhesive comprises a mixture of at least one cross-linkable pressure sensitive adhesive component and at least one non-cross-linkable pressure-sensitive adhesive component, wherein the amount of each of said components is such that the resultant adhesive can adhere to human skin for a period of up to about 7-10 days but can be removed without causing trauma to the skin.

Claims (11)

1. A reservoir or matrix transdermal delivery device for the controlled transdermal delivery of a therapeutic agent, said delivery device comprising

a therapeutic agent-containing reservoir or matrix; said reservoir or matrix comprising a first and second face; an impermeable backing layer in contact with said first face;

a pressure sensitive adhesive formulation in contact with said second face, said adhesive formulation comprising a mixture of at least one cross-linkable acrylic adhesive component and at least one non-cross-linkable acrylic adhesive component; said at least one cross-linkable acrylic adhesive and said at least one non-cross-linkable adhesive provided in such relative amounts that said adhesive formulation can adhere to human skin for a period of about 7-10 days but can be removed without causing trauma to the skin; and

a release liner releasably attached to said adhesive formulation.

2. The transdermal delivery device of claim 1 , wherein each of said cross-linkable adhesive and said non-cross-linkable adhesive is an acrylic adhesive.

3. The transdermal delivery device of claim 1 , wherein said therapeutic agent comprises a cardiovascular agent, androgenic steroid, estrogen, progestational agent, drug which acts on the central nervous system, nutritional agent, anti-inflammatory agent, antihistamine, miotic, dermatological agent, anti-spasmodic, anti-depressant, anti-cancer drug, anti-diabetic drug, anti-estrogen, hormonal agent, anti-infective agent, anti-allergenic agent, anti-pyretic agent, anti-migraine agent, tranquilizer, anti-psychotic agent, anti-emetic or anti-smoking agent.

4. The transdermal delivery device of claim 1 , wherein the cross-linkable acrylic adhesive is a self-cross-linkable acrylic adhesive component and the non-cross-linkable acrylic adhesive is a non-self-cross-linkable acrylic adhesive component.

5. A method of securing a transdermal drug delivery device to skin for a period of one to about 7 days which comprises contacting said skin with one face of said delivery device wherein at least part of said face is coated with a pressure sensitive adhesive formulation which comprises a mixture of at least one cross-linkable acrylic adhesive component and at least one non-cross-linkable acrylic adhesive component; said at least one cross-linkable acrylic adhesive and said at least one non-cross-linkable acrylic adhesive provided in such relative amounts that said adhesive formulation can adhere to skin for a period of about 7-10 days but can be removed without causing trauma to the skin.

6. The method of claim 5 , wherein the cross-linkable acrylic adhesive is a self-cross-linkable acrylic adhesive component and the non-cross-linkable acrylic adhesive is a non-self-cross-linkable acrylic adhesive component.

7. A method of securing a wound dressing, prosthesis, colostomy bag, electrode or diagnostic device to skin for a period of one to about 7-10 days which comprises contacting said skin with a portion of said dressing, prosthesis, colostomy bag, electrode or diagnostic device which has been coated with a pressure sensitive adhesive formulation which comprises a mixture of at least one cross-linkable acrylic adhesive component and at least one non-cross-linkable acrylic adhesive component; said at least one cross-linkable acrylic adhesive and said at least one non-cross-linkable acrylic adhesive provided in such relative amounts that said adhesive formulation can adhere to skin for a period of about 7-10 days but can be removed without causing trauma to the skin.

8. The method of claim 7 , wherein the cross-linkable acrylic adhesive is a self-cross-linkable acrylic adhesive component and the non-cross-linkable acrylic adhesive is a non-self-cross-linkable acrylic adhesive component.

Assignments (3)
PATENT RELEASE Recorded Dec 10, 2012
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: DEY PHARMA L.P. (F/K/A DEY, L.P.); MYLAN PHARMACEUTICALS, INC.; MYLAN BERTEK PHARMACEUTICALS INC.; MYLAN TECHNOLOGIES, INC.; SOMERSET PHARMACEUTICALS, INC.; MYLAN INSTITUTIONAL INC. (F/K/A UDL LABORATORIES, INC.); MYLAN INC.
Reel/Frame 029440/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2011
From: JACKSON, KRISTIN LAURA; MILLER, KENNETH JAMES, II
To: MYLAN TECHNOLOGIES INC.
Reel/Frame 027370/0043 →
SECURITY AGREEMENT Recorded Nov 21, 2011
From: MYLAN PHARMACEUTICALS, INC.; MYLAN BERTEK PHARMACEUTICALS INC.; MYLAN TECHNOLOGIES, INC.; MYLAN INSTITUTIONAL INC. (F/K/A UDL LABORATORIES, INC.); SOMERSET PHARMACEUTICALS, INC.; DEY PHARMA, L.P. (F/K/A DEY L.P.)
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 027270/0799 →